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ABSTRACT
Background the hallmark of the neurobehavioural 
phenotype of Williams- Beuren syndrome (WBS) is 
increased sociability and relatively preserved language 
skills, often described as opposite to autism spectrum 
disorders (aSD). However, the prevalence of aSD in WBS 
is 6–10 times higher than in the general population. 
We have investigated the genetic factors that could 
contribute to the aSD phenotype in individuals with WBS.
Methods We studied four males and four females with 
WBS and a confirmed diagnosis of aSD by the autism 
Diagnostic interview- revised. We performed a detailed 
molecular characterisation of the deletion and searched 
for genomic variants using exome sequencing.
Results a de novo deletion of 1.55 Mb (6 cases) or 
1.83 Mb (2 cases) at 7q11.23 was detected, being in 
7/8 patients of paternal origin. no common breakpoint, 
deletion mechanism or size was found. two cases 
were hemizygous for the rare t allele at rs12539160 
in MLXIPL, previously associated with aSD. inherited 
rare variants in aSD- related or functionally constrained 
genes and a de novo nonsense mutation in the UBR5 
gene were identified in six cases, with higher burden in 
females compared with males (p=0.016).
Conclusions the increased susceptibility to aSD in 
patients with WBS might be due to additive effects of 
the common WBS deletion, inherited and de novo rare 
sequence variants in aSD- related genes elsewhere in the 
genome, with higher burden of deleterious mutations 
required for females, and possible hypomorphic variants 
in the hemizygous allele or cis- acting mechanisms on 
imprinting.
InTRoduCTIon
Williams- Beuren syndrome (WBS, OMIM#194050) 
is a rare neurodevelopmental disorder resulting 
from an heterozygous deletion of 25–27 genes at 
chromosome 7q11.23, estimated to affect approx-
imately 1 in 7500 individuals.1 The WBS locus has 
a complex genomic architecture with a single copy 
region flanked by three large segmental duplica-
tions, each composed of three major blocks (A, B 
and C), located in the centromeric (c), medial (m) 
and telomeric (t) sides.2 Two types of recurrent 
rearrangements promoted by non- allelic homol-
ogous recombination (NAHR) can result in WBS 
syndrome. The most frequent is a 1.55 Mb deletion 
occurring between the medial and centromeric B 
blocks in 87% of cases. Around 10% of patients 
present a larger 1.83 Mb deletion due to a crossing 
over between centromeric and medial A blocks. The 
remaining 3% of patients with WBS show atypical 
deletions mediated by other mechanisms.3 4 The 
WBS multisystemic phenotype is characterised by 
cardiovascular disease, distinctive facies, connec-
tive tissue abnormalities and growth and endocrine 
alterations, among others.2 5 The main neurobe-
havioural hallmarks are mild to moderate intellec-
tual disability (ID), hypersociability and relative 
language preservation.6 Interestingly, the reciprocal 
duplication of 7q11.23 (OMIM#609757) results 
in a phenotype with speech delay, language impair-
ment, milder learning problems and clear social 
interaction deficits often associated with autism 
spectrum disorder (ASD).6 7
Due to their associated behavioural manifes-
tations, ASD and WBS have often been described 
as diametric opposite disorders, although this 
consideration is an oversimplification of both 
phenotypes.8 9 Moreover, several cases of WBS 
with comorbid ASD have been reported and some 
authors have suggested that ASD features should 
be considered as part of the WBS phenotype.7–18 
A recent meta- analysis of the comorbidity of ASD 
features in several well- defined genetic syndromes 
concluded that the prevalence of ASD features 
among WBS individuals is as high as 12%.19 There-
fore, the frequency of ASD is 6–10 times higher in 
individuals with WBS than in the general popula-
tion, a striking finding considering the typical WBS 
neurocognitive profile.
Potential modifiers of the common neurobe-
havioural phenotype of WBS include: (1) cis- acting 
mechanisms due to variable breakpoints altering 
flanking genes, although most patients described 
present common deletions of identical size3 17; 
(2) trans- acting factors present in the non- deleted 
hemizygous allele; (3) genetic mutations and/or 
structural variants elsewhere in the genome; (4) 
environmental events with or without epigenetic 
effects, including medical complications during 
development and early life. All these factors can 
have additive effects acting on a sensitised back-
ground caused by haploinsufficiency at the WBS 
locus.10 17 Two individuals with WBS and co- occur-
ring ASD previously reported presented hyperse-
rotonaemia and were homozygous for the short (s) 
allele in the promoter of the serotonin transporter 
SLC6A4 (5- HTTLPR), suggesting a possible modi-
fier role of this locus.14 17
In the present work, we have investigated the 
genetic factors that could contribute to the ASD 
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Figure 1 Strategy followed for the identification of second- hit genetic 
factors. DgV, Database of genomic Variants; loF, loss of function; MaF, 
minor allele frequency; SnV, single nucleotide variant.
comorbid ASD. We completed a detailed molecular character-
isation of the deletion, genotyped the reported polymorphism 
at SLC6A4 and performed a genome- wide unbiased search of 




From a cohort of 122 individuals with a diagnosis of WBS 
and confirmed 7q11.23 deletion by molecular techniques, we 
selected four males and four females aged 6–31 years with an 
associated diagnosis of ASD. The diagnosis was based on the 
direct observation by a trained psychologist and clinicians and 
confirmed in all of them using the Autism Diagnostic Interview- 
Revised (ADI- R). Written informed consent was obtained from 
all parents or legal caregivers.
7q11.23 deletion characterisation
Blood samples from probands and parents were obtained and 
genomic DNA was extracted using the Puregene DNA Purifica-
tion Kit (Gentra Systems, Big Lake, Minnesota, USA). The size 
and parental origin of the deletion was established by the analysis 
of multiple ligation- dependent probe amplification and several 
single and multiple- copy microsatellites. Refined mapping of 
deletion breakpoints was also performed by quantitative analysis 
of paralogous sequence variants as previously described.3
SLC6A4 genotyping
The polymorphism in the serotonin transporter promoter 
SLC6A4 (5- HTTLPR) was genotyped by PCR and agarose gel 
electrophoresis, using primers previously described.17
exome sequencing and analysis
Exomes were captured using the SureSelect Human All Exon V5 
capture kit (Agilent, Santa Clara, California, USA) and libraries 
were sequenced on an Illumina MiSeq platform. Paired- end 
sequences were obtained with a read length of 250 bp.
Mapping, variant calling and filtering were performed using 
BWA and GATK’s standard parameters. The hg19 human 
genome reference version was used. Variant annotation was 
performed using ANNOVAR (http://www. openbioinformatics. 
org/ annovar/), considering the variant frequency in control data-
bases: dbSNP137 (http://www. ncbi. nlm. nih. gov/ SNP/), ExAC 
(http:// exac. broadinstitute. org/), Kaviar (http:// db. systemsbi-
ology. net/ kaviar/) and an in- house database of 248 Spanish 
controls. The nature of the changes was assessed by PolyPhen 
and Condel (http:// bg. upf. edu/ fannsdb/) protein effect predic-
tion algorithms.
For CNV detection, we applied ExomeDepth and compared 
our samples with a matched aggregate reference set of 248 
in- house exomes captured and sequenced using the same 
protocol. CNVs were filtered based on their overlap with vari-
ants previously described in the Database of Genomic Variants 
and DECIPHER.20
Rare variant analysis and validation
We selected exonic variants with a minor allele frequency (MAF) 
lower than 0.002 according to several databases (previously 
mentioned) for heterozygous variants following a dominant 
inheritance model. For homozygous or compound heterozy-
gous variants, under a recessive inheritance model, we selected a 
MAF ≤0.01. Since second- hit variants would act in the presence 
of a major hit and would not be expected to solely cause ASD, 
they might be present in the general population and inherited 
from unaffected progenitors. Moreover, given the high degree 
of genetic heterogeneity of ASD, they could affect hundreds of 
genes. Taking into account the prevalence of ASD in individuals 
with WBS and the large number of genes involved, we reasoned 
that the frequency of each individual variant should be relatively 
rare and, consequently, set our MAF threshold for homozygous 
or compound heterozygous variants at ≤0.01.
To validate variants and perform segregation studies in 
parental samples, we used Sanger sequencing by capillary elec-
trophoresis (ABI PRISM 7900HT, Applied Biosystems, Foster 
City, California, USA). Primers were designed with the PRIMER3 
program (http:// www. bioinformatics. nl/ cgi- bin/ primer3plus/ 
primer3plus. cgi/ ) and PCR reactions were carried following 
standard conditions.
epistatic effects of rare variants
To study the putative contribution of epistatic effects of rare 
SNVs on gene expression deregulation in WBS, we compiled a 
list of genes previously altered in WBS by various mechanisms, 
including transcriptional dysregulation, differential methylation 
and the direct GTF2I targets. We performed a systematic litera-
ture review and selected only high- quality studies done in human 
subjects, obtaining 2251 candidate genes (online supplementary 
table 1).21–24
Analysis of ASd susceptibility loci
To study the potential contribution of common variants, we 
selected loci previously associated with ASD by Genome- Wide 
Association Studies (GWAS). Variants containing the term 
‘Asperger’ or ‘Autism’ were extracted from the Genome- Wide 
Repository of Associations between SNPs and phenotypes 
(GRASP) database V.2.0 (online supplementary table 2).25 Allele 
frequency in the WBS cohort was then compared with non- 
Finnish European (NFE) population data from ExAC by Fisher’s 
exact test and q- value and false discovery rate (FDR) values were 
calculated using the R package qvalue.26 To avoid population 
stratification, ExAC allele frequencies were compared with that 
reported in Spanish Variant Server, including data from 578 
Spanish individuals (http:// csvs. babelomics. org/).
ReSulTS
Clinical characteristic of selected patients
The study was performed in eight Spanish patients with WBS 















enet: first published as 10.1136/jm





803Codina- Sola M, et al. J Med Genet 2019;56:801–808. doi:10.1136/jmedgenet-2019-106080
Cognitive and behavioural genetics
Table 1 Clinical characteristics of the WBS individuals with associated ASD
WBS1 WBS2 WBS3 WBS4 WBS5 WBS6 WBS7 WBS8
Birth year 1987 1985 2000 2006 2002 2008 2001 2010
Gender F M M M F M F F
Relevant family history No No Yes* No No Yes† No No
Age at WBS diagnosis 7 y 3 y 5 m 3 m 3 m 2 y 5 y 1 y
Age at ASD diagnosis 4 y 10 y 6 y 5 y 12 y 5 y 3 y 5 y
ADI- R   
  A 22 11 11 22 14 10 19 18
  B (V) – 7 4 – – – – –
  B (NV) 10 – – 12 7 4 14 9
  C 8 4 6 8 8 6 9 5
  D 5 4 1 5 3 4 4 5
IQ (WISC- R)     40   <40 41 <40   
Other neurological symptoms   ADHD ADHD   Behavioural 
problems
Epilepsy, ADHD   ADHD
Cardiovascular disease ND SVAS Coarctation of 
aorta
SVAS SVAS SVAS SVAS ND
Endocrine abnormalities ND ND ND ND Early puberty ND Early puberty Subclinical 
hypothyroidism
ADI- R scores: A. Social interaction (cut- off: 10); B. Communication and language, (V): verbal (cut- off: 8), (NV): non- verbal (cut- off: 7); C. Restricted and repetitive behaviours (cut- 
off: 3); D. Developmental alterations earlier than 36 months (cut- off: 1).
*Paternal aunt with ASD and severe ID.
†Father committed suicide.
ADHD, attention deficit hyperactivity disorder; ADI- R, Autism Diagnostic Interview- Revised; ASD, autism spectrum disorder; F, female; IQ, intellectual quotient; M, male; m, month; 
ND, not detected by standard testing; SVAS, supravalvular aortic stenosis; WBS, Williams- Beuren syndrome; WISC- R, Wechsler Intelligence Scale for Children- Revised; y, year.




allele Genome- wide Genome- wide rare loF SnVs
origin GTF2IRD2 Size (Mb) SnVs CnVs ASd candidate genes loF intolerant genes
WBS1 Pat 1M/3T 1.55
WBS2 Pat 2M/2T 1.55 T at rs12539160
WBS3 Pat 1M/3T 1.55 SIK1 partial dupPI
WBS4 Pat 1M/2T 1.83 CC2D1A
c.1357- 2A>CPI
WBS5 Pat 2M/2T 1.55 PYHIN1 p.(Arg373*)MI SEC24C c.2682+2A>GMI
UBR5
p.(Arg633*)DN
WBS6 Pat 1Ch/1M/2T 1.55 T at rs12539160 AGAP1
c.1051- 2A>TPI
WBS7 Mat 2M/2T 1.55 DUSP22 delNM USP45 p.(Glu220*)MI CXXC1 p.(Ser222Leufs*7)NM
WBS8 Pat 1M/2T 1.83 PIK3CG p.(Glu14Glyfs*147)PI MED26 c.147+2T>CPI
EPHB1 p.(Ser435ProfsTer13)MI
*Stop codon.
Ch, chimeric- type copies; DN, de novo; del, deletion; dup, duplication; LoF, loss of function; M, medial- type copies; MI, maternally inherited; Mat, de novo, maternal chromosome; 
NM, not maternal (father not available); PI, paternally inherited; Pat, de novo, paternal chromosome; T, telomeric- type copies; WBS, Williams- Beuren syndrome.
a multidisciplinary clinic and complete neurobehavioural evalu-
ation due to a comorbid diagnosis of ASD. Their main clinical 
characteristics are summarised in table 1. All patients fulfilled 
criteria in the social interaction and restrictive behaviour 
domains while two of them (WBS2 and WBS3) did not reach the 
verbal communication domain threshold. Family history of ASD 
or psychiatric disorders was positive on the paternal side in two 
cases (WBS3 and WBS6) and negative in the others (table 1).
detailed characterisation of the 7q11.23 deletion
To define potential cis- acting factors in the deleted allele, we 
characterised all deletions at the molecular level including deter-
mination of the parental origin. All rearrangements were de novo 
and all but one (7/8) were of paternal origin (table 2). The most 
common 1.55 Mb deletion was found in 6/8 patients, whereas 
2/8 carried the larger recurrent 1.83 Mb deletion mediated by 
NAHR between A blocks (figure 2). In two patients (WBS1 and 
WBS3), the common 1.55 Mb deletion had been mediated by an 
inversion in the transmitting progenitor.
Since GTF2IRD2 has been postulated as a possible modulator 
of WBS cognitive phenotype,27 we analysed the deletion break-
points to assess the number of functional copies of this gene 
in the patients (figure 2). As expected, the deletions mediated 
by A blocks included the entire medial B block with a copy of 
GTF2IRD2, resulting in a loss of one functional copy (1M/2T: 
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Figure 2 Schematic representation of the Williams- Beuren syndrome 
(WBS) locus, showing the two most common deletions and the gene 
content of the B block. the B block contains three genes: GTF2I, NCF1 
and GTF2IRD2. Whereas GTF2I and NCF1 have a single functional copy 
located at the medial B block, GTF2IRD2 has two functional copies, 
located at the medial (GTF2IRD2) and telomeric (GTF2IRD2B) B blocks. the 
1.55 Mb deletion is mediated by B blocks and results in a chimeric medial- 
centromeric block, with the number of functional copies of GTF2IRD2 and 
NCF1 depending on the deletion breakpoint. in contrast, the 1.83 Mb 
deletion is mediated by a blocks, resulting in the loss of the medial and 
centromeric B blocks with functional copies of GTF2IRD2 and NCF1.
patients with inversion- mediated deletions had a 1M/3T geno-
type, originated from the loss of a medial copy and a gain of a 
telomeric copy of GTF2IRD2. Among the patients with 1.55 Mb 
deletions, three had breakpoints before GTF2IRD2, with no 
change in the number of functional copies (2M/2T), whereas in 
one patient the breakpoint occurred within GTF2IRD2, creating 
a chimeric copy (Ch) between the medial gene and the centro-
meric pseudogene (1Ch/1M/2T) (table 2). The breakpoints also 
affect the number of NCF1 copies, by either deleting or not one 
of the functional copies.
hemizygous variants in the 7q11.23 region
To look for trans- acting factors in the 7q11.23 allele present in 
hemizygosity, we analysed the entire captured region within the 
WBS common deletion locus (chr7:72 700 000–74 250 000) 
looking for over- represented rare and common variants, shared 
haplotypes and rare deleterious SNVs. For over- represented 
variants, we compared allele frequencies of all described 
hemizygous variants (n=32) in our cohort to those reported 
in ExAC for European population. Variants with significantly 
different frequencies in ExAC and Spanish Variant Server were 
excluded to avoid population stratification. Due to the small 
sample, none of the variants reached statistical significance, but 
we identified a nearly significant association (p=0.076) with 
rs12539160, which was present in two individuals (WBS2 and 
WBS6). This synonymous variant located near an exon- intron 
boundary of MLXIPL had been previously associated with 
ASD in a GWAS.28 Taking advantage of the hemizygosity of 
SNPs in the deleted single- copy region, we extracted phased 
haplotypes in this interval to study if a common haplotype was 
shared between individuals. Two linkage disequilibrium blocks 
were identified from rs1128349 to rs13227841 (DNAJC30 
to WBSCR28) and from rs17851629 to rs2074667 (located 
in GTF2IRD1). Allele frequencies of the tag markers did not 
differ significantly from those in the general population and 
no common shared haplotype was identified in our cohort. In 
addition, we looked for rare SNVs in the single- copy region of 
the WBS locus. Only hemizygous variants with a MAF <0.01 
were selected. After filtering for exonic variants and excluding 
synonymous SNVs with no functional effect, we remained with 
two non- synonymous variants in genes MLXIPL and TBL2 
predicted as tolerant by various protein effect prediction algo-
rithms ((SIFT (sorting intolerant from Tolerant), PolyPhen 
(Polymorphism Phenotyping) and Condel)). No rare variants 
were identified at GTF2I, NCF1 and GTF2IRD2, the genes in 
the flanking segmental duplications.
Genome-wide analysis of rare variants
Copy number variants
We also studied the presence of additional rearrangements that 
could explain the autistic symptoms in our cohort. In addition 
to the WBS 7q11.23 deletion, we observed an average of 25 
CNVs per patient ranging from 170 bp to 334 kb. None of the 
additional rearrangements overlapped with known genomic 
disorders or was previously associated with neurodevelopmental 
disorders and all overlapped with previous CNVs described in 
the general population.29 Only two CNVs comprised ASD candi-
date genes (SIK1 and DUSP22) (online supplementary table 3).30 
The CNV involving SIK1 was a partial duplication affecting the 
last two exons of the gene, paternally inherited in patient WBS3. 
The heterozygous deletion completely containing DUSP22 was 
found in patient WBS7 and not in her mother, but paternal 
sample was unavailable.
Rare single nucleotide variants
We prioritised deleterious variants present in a list of candi-
date genes from - Simons Foundation Autism Research Initiative 
(SFARI) (n=791) (online supplementary table 3) and/or highly 
constrained genes, as previous studies have shown that genes 
predisposing to ASD carry a low burden of disrupting mutations 
in the general population.30 31 Constrained genes were defined 
as those with a probability of being loss of function (LoF) intol-
erant (pLI >0.9) according to ExAC.32 LoF and missense vari-
ants predicted as damaging by both SIFT and PolyPhen were 
considered deleterious variants.
We detected a total of 38 rare deleterious SNVs in 34 candi-
date genes (online supplementary table 4). All LoF variants 
(n=6) were validated and segregation studies were performed 
on all samples, showing a de novo variant in the UBR5 gene 
in case WBS5 (table 2). De novo variants in the UBR5 gene, 
two missense and one LoF, have been previously described in 
ASD individuals.33–35 WBS5 is a severely affected female who 
presented an obsessive ritualistic behaviour, hypersensitivity to 
noise and physical stimuli, had not developed language and did 
not show eye contact.
As for highly constrained genes, excluding candidate genes, 
we detected 68 SNVs in 65 genes, including four LoF mutations 
(table 2). All genes selected on the basis of being LoF intolerant 
but harbouring a LoF in our cohort were brain- expressed and 
some had been previously associated with psychiatric and neuro-
developmental disorders, such as SEC24C, CXXC1 and EPHB1, 
which was mutated in two patients with WBS.36–39
Epistatic effects of rare variants
To study if second- hit variants could be disrupting genes already 
altered in WBS and act by an epistatic effect, we intersected a 
manually curated list of genes with altered expression in WBS 
with the list of mutated genes (figure 3). The results showed 
that 20 of mutated genes were also altered in WBS. Two of them 
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Figure 4 gender (male vs female) comparison of the average number 
of rare variants in Williams- Beuren syndrome- autism spectrum disorders 
cases. Statistical significance in all tests was calculated using a two- sided 
Student’s t- test, excluding SnVs of the X and Y chromosomes from the 
analysis. (a) Deleterious variants in candidate genes. (B) all rare variants. 
SnV, single nucleotide variant.
Figure 3 Overlap between candidate and functionally constrained genes 
mutated in our cohort and genes altered in Williams- Beuren syndrome 
(WBS).
Burden of rare deleterious mutations, increased in females
In total, six patients with WBS with ASD carried, in addition 
to the specific de novo 7q11.23 deletion, one to three strong 
candidate rare genetic variants (CNV and/or SNV) that could 
contribute to the ASD phenotype, either inherited or de novo 
(table 2).
Since ASD is four times more prevalent in males than females, 
it has been suggested that females have a higher risk threshold 
and require a higher genetic load to develop the disorder.40 
To examine if females in our cohort carried a higher genetic 
burden, we compared the frequency of rare deleterious vari-
ants in ASD candidate genes between males (n=4) and females 
(n=4) (figure 4). The results showed a statistically significant 
increase (p=0.016) in the number of total mutations per patient 
in females ( 
−
x = 6 , SD=1.7) compared with males ( 
−
x = 3 , 
SD=1.2). This effect was not seen when comparing the burden 
of all rare variants between genders (p=0.51).
Association study with candidate ASd genes
To study the potential role of common variants, we analysed the 
loci previously associated with ASD and compared their varia-
tion frequency in our cohort with that of NFE ExAC popula-
tion. A total of 645 single- nucleotide markers located in coding 
regions were analysed, of which only 13 obtained a significant 
p value (p<0.05) and none passed FDR correction. For 10 of 
the significantly over- represented SNVs in our cohort, the 
over- represented allele corresponded to the risk allele, whereas 
it was the protector allele for the 3 remaining. Three of the 
markers had been previously described as Expression Quantita-
tive Trait Loci (eQTL) in brain, with rs2275477 associated with 
increased expression of OSCP1 and rs4823086 and rs5749088 
with transcript RP1.130H16.16/CCDC157.41 We also identified 
a nominally significant increase in the frequency of rs2135720, 
a non- synonymous SNP within PCDH15 associated with lipid 
traits.42
Finally, we also genotyped two promoter variants at SLC6A4 
not captured in exome data that had been proposed as modifiers 
for the phenotypic outcome in WBS in two patients with autistic 
symptoms and hyperserotonaemia. In our cohort, the genotype 
frequencies were similar to those found in population of Euro-
pean origin, with 3/8 individuals homozygous for the major long 
variant (l), 4/8 presenting an heterozygous genotype (l/s) and 1/8 
individual being homozygous for the s allele.
dISCuSSIon
We have performed a genome- wide comprehensive analysis to 
investigate possible genetic factors in eight individuals presenting 
with both diagnoses of WBS and ASD. To date, the analysis of 
exome data failed to reveal genetic variants that could explain 
the variance of the social behaviour phenotype in a cohort of 85 
patients with WBS without comorbid ASD,43 and the only locus 
suggested to act as a modifying factor was the serotonin trans-
porter SLC6A4 (5- HTTLPR), based on two individuals with 
WBS and ASD who had hyperserotonaemia and were homozy-
gous for the ss polymorphism at the gene promoter.17 However, 
the results in our cohort show genotype frequencies similar to 
those of the general population and do not support a role of 
SLC6A4.
The characterisation of the deletion showed no atypical rear-
rangements and different breakpoints in the patients, excluding 
the alteration of flanking genes as a major cause. In the studied 
patients the deletion had originated in the paternal allele in 
seven of eight, suggesting that epigenetic control mechanisms 
could influence ASD risk in WBS. This parental bias was not 
present in our larger cohort of WBS without comorbid ASD 
(n=374 trios) as the origin of the deletion was 50% maternal 
and 50% paternal. There are some evidences supporting the 
imprinting of the 7q11.23 region based on expression of FKBP6 
and GTF2I.44–46 However, in a recent study of six patients with 
WBS and ASD, the deletion was of maternal origin in four out of 
six patients.47 Collectively, there is suggestive evidence regarding 
a possible role of genetic imprinting, but not enough data to 
confirm it, which demands characterisation of the deletion and 
parental origin in additional individuals with WBS and ASD to 
confirm whether imprinting can influence phenotypic variability.
Besides deletion origin and breakpoints, hemizygous variants 
unmasked in the deleted region could also act as second- hit 
modifying factors. The detailed analysis of SNVs did not reveal 
any common haplotype or any rare variant in the coding regions 
of GTF2I or GTF2IRD2. However, the analysis of common vari-
ants revealed an over- representation of a relatively rare hemizy-
gous variant previously associated with ASD (rs12539160).28 It 
has a MAF of 0.06 in European population and of 0.03 in the 
Spanish population but it was found in two patients (0.25) of our 
cohort, representing an eightfold increase in frequency.32 While 
not meeting strict criteria for statistical significance (p=0.076), 
this finding deserves additional investigation in future studies. 
In a recent study, exome data of 85 patients with WBS was anal-
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account for the variance in the social behaviour of these patients.43 
Together with the genotyping of our cohort of non- autistic WBS, 
this variant (rs12539160) was found with a frequency of 0.0573 
among 157 WBS individuals which is similar to general popula-
tion. Although this variant lies in the intronic region of MLXIPL, 
mainly involved in lipid abnormalities, deregulation of the same 
or other nearby gene either by this SNP or other risk variants in 
linkage disequilibrium not detected by exome sequencing might 
contribute to ASD risk in WBS.
We also studied genetic variation at a genome- wide level. 
Regarding CNVs, no additional large (>500 kb) or pathogenic 
rearrangement was identified. Likewise, previous studies eval-
uating second- hit CNVs in genomic disorders showed that 
additional rearrangements were more frequent in disorders of 
variable expressivity than in syndromic entities. In fact, only 5% 
of individuals with WBS carried a second event, similar frequency 
than in the control population, suggesting that additional large 
CNVs may cause a more severe phenotype and/or be incompat-
ible with life.48 However, relatively small CNVs altering ASD 
candidate genes and therefore potential contributors to the ASD 
phenotype were found in two patients, a partial duplication of 
the last two exons of SIK1, and a complete heterozygous dele-
tion of DUSP22.
The analysis of rare deleterious SNVs on ASD candidate 
and functionally constrained genes uncovered several brain- 
expressed genes that harbour LoF variants in our cohort. Among 
those, we detected a de novo stop mutation affecting UBR5, an 
E3 ubiquitin- protein ligase in a severely affected female. There-
fore, the presence of WBS and ASD in this individual is probably 
due to the co- occurrence of two mechanistically unrelated de 
novo events, the WBS deletion and the UBR5 mutation.
However, the increased prevalence of ASD features in WBS 
and the low frequency of de novo events suggest that other 
genetic factors of smaller effect may be influencing the ASD risk 
in most cases. In fact, we have identified several rare variants in 
ASD candidate genes. Two of the genes harbouring LoF muta-
tions, EPHB1 and AGAP1, have been found deregulated in WBS, 
suggesting a possible epistatic effect. AGAP1 was hypermethyl-
ated in patients with WBS compared with individuals with the 
reciprocal duplication, which is associated with a phenotype of 
language impairment, anxiety and increased risk of ASD and 
schizophrenia.24 49–51 EPHB1 was underexpressed in patients 
with WBS and individuals with atypical deletions and low IQ. 
Inherited mutations in those genes would result in further dereg-
ulation of the expression already altered by the WBS deletion21 
and higher risk for a more severe phenotype.
Globally, six of the eight patients with WBS with ASD carried, 
in addition to the specific de novo deletion at the 7q11.23 locus, 
one to three rare genetic variants (CNV and/or SNV) altering 
candidate genes that could contribute to the ASD phenotype. 
Consequently, a proportion of cases of WBS with associated 
ASD could be explained by the same factors influencing ASD 
risk in the general population with a threshold model. Given the 
increased risk for ASD in WBS, the WBS deletion would act as a 
predisposing factor facilitating the role of other genetic (inher-
ited or de novo) and/or environmental factors by acting on an 
already sensitised background.
Interestingly, the average number of rare deleterious vari-
ants in candidate genes was significantly higher in females than 
males, an effect not observed when considering all rare variants. 
Although our small sample size requires caution interpreting the 
results, this difference could support the higher risk threshold 
requiring higher genetic load in females to develop ASD, or 
could just be explained by the fact that females in our cohort had 
a more severe presentation than males. Further studies assessing 
the difference in prevalence and severity of ASD features 
between genders in individuals with WBS will help clarify if the 
female protective effect has a role in the expressivity of disorders 
of full penetrance.
Finally, we assessed the contribution of common variation by 
looking for over- represented variants previously associated with 
ASD. Although none of the variants passed FDR correction, three 
markers with nominal p values had been previously described as 
eQTLs in brain and may have a direct functional effect. However, 
our study is limited by the fact that most common variation is 
not covered by exome sequencing, as it resides in non- coding 
regions. Currently, common variation seems to explain at least 
20% of ASD liability.52 Therefore, further studies regarding the 
role of common variants in autism will provide a necessary basis 
for future studies.
In summary, our work represents a thorough assessment of 
second- hit modifier genetic factors in individuals with WBS 
and associated ASD. Similar to previous reports, patients did 
not differ in deletion breakpoints, discarding the role of atyp-
ical rearrangements. However, in seven of eight the deletion 
had originated in the paternal allele, a factor that had not been 
addressed in previous studies. In addition, two individuals 
carried a relatively rare hemizygous variant previously associ-
ated with ASD, representing an eightfold increase with respect 
to the general population. Inherited rare variants and a de novo 
nonsense mutation in ASD- related or functionally constrained 
genes were identified in six cases, with higher burden in females 
compared with males. Taken together, these results suggest that 
imprinting mechanisms, trans- acting factors in the remaining 
allele and inherited or de novo rare sequence variants elsewhere 
in the genome may play a role in the susceptibility to ASD in 
WBS. Therefore, similar factors influencing ASD risk in the 
general population also shape phenotypic variability in disorders 
with full penetrance.
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